Recurrent Melanoma Suspended Phase 1 / 2 Trials for Ipilimumab (DB06186)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Suspended1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01769222Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal CancerTreatment